Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents
- 16 August 2010
- Vol. 28 (36) , 5864-5870
- https://doi.org/10.1016/j.vaccine.2010.06.059
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trialsThe Lancet, 2010
- Australia's Winter with the 2009 Pandemic Influenza A (H1N1) VirusNew England Journal of Medicine, 2009
- A Novel Influenza A (H1N1) Vaccine in Various Age GroupsNew England Journal of Medicine, 2009
- Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted VaccineNew England Journal of Medicine, 2009
- Response to a Monovalent 2009 Influenza A (H1N1) VaccineNew England Journal of Medicine, 2009
- Novel Swine-origin Influenza Virus A (H1N1): The First Pandemic of the 21st CenturyJournal of the Formosan Medical Association, 2009
- Immunogenicity and reactogenicity of a trivalent influenza split vaccine in previously unvaccinated children aged 6–9 and 10–13 yearsVaccine, 2007
- Immunogenicity and Reactogenicity of 1 versus 2 Doses of Trivalent Inactivated Influenza Vaccine in Vaccine‐Naive 5–8‐Year‐Old ChildrenThe Journal of Infectious Diseases, 2006
- Immunization With Trivalent Inactivated Influenza Vaccine in Partially Immunized ToddlersPediatrics, 2006
- Immunizing Kids Against Flu May Prevent Deaths Among the ElderlyScience, 2004